Oxford Biomedica PLC Oxford Biomedica to present at the ASGCT
April 30 2019 - 8:35AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
30 April 2019
Oxford Biomedica to present at the Annual Meeting of the
American Society of Gene & Cell Therapy
Oxford, UK - 30 April 2019: Oxford Biomedica plc (LSE:OXB), a
leading gene and cell therapy group, today announced that data from
five studies will be highlighted in two oral presentations and
three poster sessions at the American Society of Gene & Cell
Therapy 22(nd) Annual Meeting, taking place between 29 April and 2
May in Washington, DC, USA.
An oral presentation by OXB will highlight previously published
preclinical data from an investigation of 5T4 expression and the
potential of a CAR-T therapy, OXB-302, as a treatment for
haematological and solid tissue cancers. In a separate oral
presentation, details from the ongoing SUNRISE-PD Phase 1/2 trial
of AXO-Lenti-PD for the treatment of Parkinson's disease will be
shared by OXB's partner, Axovant Gene Therapies.
Additional poster presentations by OXB scientists will highlight
preclinical data on OXB-203, OXB's programme for wet age-related
macular degeneration, as well as presentations on OXB's
LentiVector(R) manufacturing process.
Dr Kyriacos Mitrophanous, Chief Scientific Officer of Oxford
Biomedica, said:
"Our scientific presence at ASGCT demonstrates the strength of
our LentiVector(R) platform. We look forward to highlighting the
potential of gene and cell therapy with lentiviral vectors, both in
our own proprietary programmes and in those of our partners, to
further advance our mission to deliver life-changing therapies to
patients."
Oral presentations:
Title: Pre-Clinical Investigations of CAR T Cells Directed
Against the Tumour Antigen 5T4 (OXB-302) in Solid Tumor Models
(Abstract #373)
Session: Immunotherapy 1
Date and time: Tuesday, 30 April 2019, 9.45-10am ET
Note: includes new data as well as data previously presented at
the International Symposium on Immunotherapy, 12-13 May 2017 and
published in the Journal of Immunotherapy*
Title: AXO-Lenti-PD: A Second-Generation Lentiviral Gene Therapy
for the Treatment of Parkinson's Disease (Abstract #222)
Session: Gene replacement for neurological diseases
Date and time: Tuesday, 30 April 2019, 3.30-3.45pm ET
Poster presentations:
Title: Highly Efficient Clearance of Residual DNA During Viral
Vector Biogenesis Using Co-Expressed Secreted Nucleases (Abstract
#443)
Session: Poster Session II: RNA Virus vectors
Date and time: Tuesday, 30 April, 5.00-6.00pm ET
Title: OXB-203, a Lentiviral Vector Expressing Aflibercept as a
Single Dose, Long-Term Treatment for Wet Age-Related Macular
Degeneration (Abstract #544)
Session: Poster Session II: Neurologic Diseases
Date and time: Tuesday 30 April 2019 5.00-6:00pm ET
Title: GMP Manufacturing of Lentiviral Vectors: Scale-Up
Considerations (Abstract #893)
Session: Poster session III: Vector and cell engineering,
production or manufacturing II
Date and time: Wednesday, 1 May 5.00-6.00pm ET
*DOI: 10.1097/ CJI.0000000000000203
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate T: +44 (0)1865 783 000
Development & IR T: +44 (0)1865 783 000
Sarah MacLeod, Head of Communications T: +44 (0)1865 954 161 / E: ir@oxb.com
T: +44 (0)7747 602 739 / E: media@oxb.com
Consilium Strategic Communications T: +44 (0)20 3709 5700
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK
Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations,
through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than
430 people. For more information, visit www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAIMMTTMBTJBLL
(END) Dow Jones Newswires
April 30, 2019 08:35 ET (12:35 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024